Clinical Trial Update: Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing vandetanib (ZD6474) in combination with pemetrexed to pemetrexed alone in second-line non-small cell lung cancer has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-03-26